Abelacimab, *a monoclonal antibody that targets the inactive form of factor XI and prevents its activation*, has been compared to Rivaroxaban in a recent clinical trial focused on atrial fibrillation patients, a condition that heightens stroke risk.

**Key Findings:**
-99% reduction in free factor XI levels with a 150 mg dose of Abelacimab and 97% reduction with a 90 mg dose.
-An unexpected decrease in bleeding events.
-The rate of major or clinically relevant nonmajor bleeding was significantly lower with Abelacimab: 3.2 events per 100 person-years with the 150 mg dose, 2.6 events with the 90 mg dose, compared to 8.4 events per 100 person-years with Rivaroxaban.

The results indicate that abelacimab offers a more targeted approach with fewer side effects, presenting a potential improvement over Rivaroxaban for the patients.

Source: NEJM| [Read Full Story] (https://www.nejm.org/doi/full/10.1056/NEJMoa2406674)